FMP
Enter
API Tools
Extras
Kindred Biosciences, Inc.
KIN
NASDAQ
Inactive Equity
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
9.25 USD
0.01000023 (0.108%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
